Anti Micro Albuminuric Effect of Spironolatone with or without Losartan in Diabetic type II Patients
Phase 2
Completed
- Conditions
- micrialbuminuria in diabetic type 2.Glomerular disorders in diabetes mellitus
- Registration Number
- IRCT138806211241N2
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
This study will done in 35-75 years old diabetic patient with microalbuminuria. Exclusion criteria: 1)systolic blood pressure > 180mmHg; 2)Diastolic blood pressure > 110mmHg; 3)Serum k > 5.5 mg/dl; 4)CVA or MI in 6 month ago; 5)Treatment whit corticosteroids, NSAIDs, immunosuppressive; 6)Patients whit renovascular disease, obstructive uropathy, collagenous disease, Malignancy, alcohol users, addiction; 7)Pregnant or breast fed women; 8)HbA1C > 8%.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of urinary microalbuminuria. Timepoint: Before treatment and 12 weeks after treatment. Method of measurement: Laboratory.
- Secondary Outcome Measures
Name Time Method Measurement of sodium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Potassium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Laboratory.;Creatinine. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Urea. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Hypertension. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: The barometer.